(State or other jurisdiction of
2000 Galloping Hill Road, Kenilworth, NJ
(Address of principal executive offices)
Registrant’s telephone number, including area code: (908) 740-4000
(Former name or former address, if changed since last report.)
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Submission of Matters to a Vote of Security Holders.
The Annual Meeting of Shareholders of Merck & Co., Inc. (the "Company") was held on May 23, 2017.
Shareholders voted on the matters set forth below:
All of the following persons nominated were elected to serve as directors and received the number of votes set forth opposite their respective names:
Leslie A. Brun
Thomas R. Cech, Ph.D.
Pamela J. Craig
Kenneth C. Frazier
Thomas H. Glocer
Rochelle B. Lazarus
John H. Noseworthy, M.D.
Carlos E. Represas
Paul B. Rothman, M.D.
Patricia F. Russo
Craig B. Thompson, M.D.
Wendell P. Weeks
Peter C. Wendell
A proposal to approve, by non-binding advisory vote, the compensation of our Named Executive Officers received the following votes:
A proposal to approve, by non-binding advisory vote, the frequency of future votes to approve the compensation of our Named Executive Officers received the following votes:
A proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for 2017 received the following votes:
A shareholder proposal concerning employee practices in Israel/Palestine received the following votes:
A shareholder proposal requesting a report on conducting business in conflict-affected areas received the following votes:
A shareholder proposal requesting a report on Board oversight of product safety and quality received the following votes:
Based on the voting results set forth in (b) (3) above, the Company's Board of Directors has determined that the Company will hold an annual non-binding advisory vote on the compensation of the Named Executive Officers listed in the proxy statement for its Annual Meeting of Shareholders.
Merck & Co., Inc.
/s/ Karen L. Mealey
Name: Karen L. Mealey
Title: Assistant Secretary